208 related articles for article (PubMed ID: 29518351)
1. Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer.
Zhao X; May A; Lou E; Subramanian S
Transl Res; 2018 Jun; 196():62-70. PubMed ID: 29518351
[TBL] [Abstract][Full Text] [Related]
2. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
3. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoints as a Target for Colorectal Cancer Treatment.
Passardi A; Canale M; Valgiusti M; Ulivi P
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635639
[TBL] [Abstract][Full Text] [Related]
5. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
6. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
[TBL] [Abstract][Full Text] [Related]
7. Development and interpretation of a pathomics-based model for the prediction of microsatellite instability in Colorectal Cancer.
Cao R; Yang F; Ma SC; Liu L; Zhao Y; Li Y; Wu DH; Wang T; Lu WJ; Cai WJ; Zhu HB; Guo XJ; Lu YW; Kuang JJ; Huan WJ; Tang WM; Huang K; Huang J; Yao J; Dong ZY
Theranostics; 2020; 10(24):11080-11091. PubMed ID: 33042271
[TBL] [Abstract][Full Text] [Related]
8. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
9. Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer.
Zhou Y; Li H; Zhang Y; Zhao E; Huang C; Pan X; Shu F; Liu Z; Tang N; Li F; Liao W
Cancer Lett; 2024 May; 589():216836. PubMed ID: 38556105
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.
Lamberti C; Lundin S; Bogdanow M; Pagenstecher C; Friedrichs N; Büttner R; Sauerbruch T
Int J Colorectal Dis; 2007 Feb; 22(2):145-52. PubMed ID: 16724208
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic Resistance of Solid Tumors to Immune Checkpoint Blockade Therapy.
Zhao X; Subramanian S
Cancer Res; 2017 Feb; 77(4):817-822. PubMed ID: 28159861
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathological classification of colorectal cancer.
Müller MF; Ibrahim AE; Arends MJ
Virchows Arch; 2016 Aug; 469(2):125-34. PubMed ID: 27325016
[TBL] [Abstract][Full Text] [Related]
14. [Development of immune checkpoint inhibitor in colorectal cancer].
Kitano S
Nihon Rinsho; 2016 Nov; 74(11):1818-1820. PubMed ID: 30550688
[TBL] [Abstract][Full Text] [Related]
15. SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability.
Roh SA; Kwon YH; Lee JL; Kim SK; Kim JC
Anticancer Res; 2021 Nov; 41(11):5431-5444. PubMed ID: 34732412
[TBL] [Abstract][Full Text] [Related]
16. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
[TBL] [Abstract][Full Text] [Related]
17. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy and patients treated for cancer with microsatellite instability.
Colle R; Cohen R; Cochereau D; Duval A; Lascols O; Lopez-Trabada D; Afchain P; Trouilloud I; Parc Y; Lefevre JH; Fléjou JF; Svrcek M; André T
Bull Cancer; 2017 Jan; 104(1):42-51. PubMed ID: 27979364
[TBL] [Abstract][Full Text] [Related]
19. Mutational profiling of colorectal cancers with microsatellite instability.
Lin EI; Tseng LH; Gocke CD; Reil S; Le DT; Azad NS; Eshleman JR
Oncotarget; 2015 Dec; 6(39):42334-44. PubMed ID: 26517354
[TBL] [Abstract][Full Text] [Related]
20. Marine ω-3 polyunsaturated fatty acids and risk of colorectal cancer according to microsatellite instability.
Song M; Nishihara R; Wu K; Qian ZR; Kim SA; Sukawa Y; Mima K; Inamura K; Masuda A; Yang J; Fuchs CS; Giovannucci EL; Ogino S; Chan AT
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25810492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
